20/20 Biolabs, Inc. (AIDX) shareholders
Close on Nov 13, 2026Market cap $2.61MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Jonathan M Cohen | 1,833,750 | 16.80% | 13D (active) | Mar 3, 2026 |
| Full Succeed International Limited Joint filing with Nengyuan Pan (6.30%), Wei Lu (6.30%) | 651,465 | 6.30% | 13G (passive) | Feb 19, 2026 |
| Streeterville Management, LLC Joint filing with Streeterville Capital LLC (9.90%), John M Fife (9.90%) | 543,680 | 9.90% | 13G (passive) | Feb 25, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AIDX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Cresset Asset Management, LLC | 240,122 | 1.88% | $132.00K | −24,246 | 0.00% |
| Hrt Financial LP | 89,273 | 0.70% | $49.00K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 52,087 | 0.41% | $28.65K | New | 0.00% |
| Geode Capital Management, LLC | 49,141 | 0.38% | $27.01K | New | 0.00% |
| Atlantic Union Bankshares Corp | 35,099 | 0.27% | $19.29K | New | 0.00% |
| Vanguard Capital Management LLC | 24,530 | 0.19% | $13.49K | New | 0.00% |
| Citadel Advisors LLC | 23,205 | 0.18% | $12.76K | +6,978 | 0.00% |
| Bank Of America Corp /De/ | 13,024 | 0.10% | $7.15K | New | 0.00% |
| Susquehanna International Group, Llp | 10,014 | 0.08% | $5.51K | New | 0.00% |
| McDonald Partners LLC | 2,800 | 0.02% | $1.54K | New | 0.00% |
| Signaturefd, LLC | 767 | 0.01% | $422 | New | 0.00% |
| Morgan Stanley | 283 | 0.00% | $156 | New | 0.00% |
| Allworth Financial LP | 172 | 0.00% | $95 | +142 | 0.00% |
| Toth Financial Advisory Corp | 100 | 0.00% | $55 | −57 | 0.00% |
| UBS Group AG | 3 | 0.00% | $2 | −8,311 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 15 | 1M | 4.2% | 10 / 2 | 3 / 2 | 0M | 0M |
| Q1 2026 | 7 | 0M | 2.4% | 7 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of AIDX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Nasdaq Composite Index Fund | 5,319 | 0.04% | $4.63K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jonathan M. Cohen | Chief Executive Officer, Director, 10% owner | 1,366,400 | 10.70% | Mar 4, 2026 |
| Jiming Zhou | Chief Operating Officer | – | – | Apr 6, 2026 |
| Alan B. Bergman | Chief Financial Officer | – | – | Apr 6, 2026 |
| Ron Baker | Chief Business Officer | – | – | Feb 17, 2026 |
| Michael Saul Lebowitz | Chief Scientific Officer | – | – | Feb 17, 2026 |
| Richard M. Cohen | Director | 7,700 | 0.06% | Feb 23, 2026 |
| John G. Compton | Director | 14,335 | 0.11% | Feb 23, 2026 |
| John Woodson Rollins | Director | 30,275 | 0.24% | Feb 23, 2026 |
| Michael A. Ross | Director | 31 | 0.00% | Feb 23, 2026 |
| Prasanth Reddy | Director | – | – | Feb 17, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John Woodson Rollins Director | Feb 19, 2026 | Conversion | +6,135 | – | – | 30,275 |
| John Woodson Rollins Director | Feb 19, 2026 | Conversion | +13,029 | – | – | 24,140 |
| Michael A. Ross Director | Feb 19, 2026 | Conversion | +31 | – | – | 31 |
| John G. Compton Director | Feb 19, 2026 | Conversion | +7,669 | – | – | 14,335 |
| Richard M. Cohen Director | Feb 19, 2026 | Conversion | +7,700 | – | – | 7,700 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 9 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of 20/20 Biolabs's stock actually held short. Settlement fails (shares not delivered on time) peaked at 19,970 shares on Aug 28, 2026 over the last 90 days.
See a number that looks wrong?